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The RP dipeptide motif is highly conserved in the third hypervariable region (V3 loop) of the extracellular envelope
glycoprotein of different types of HIV isolates. In view of this, we have designed and synthesized a construction referred
to as ‘‘template assembled synthetic peptide’’ (TASP), in which a lysine-rich short polypeptide was used as a template to
covalently anchor arrays of tripeptides, such as RPR, RPK, or KPR. The pentavalent presentation, 5(RPR)-, 5(RPK)-, or 5(KPR)-
TASP, molecules manifested maximum inhibitory activity on HIV infection with a 50% inhibitory concentration value of 1– 5
mM, respectively. Structure and inhibitory-activity relationship studies using analogs of 5(KPR)-TASP indicated that the
positively charged side chains of the K and R residues in the tripeptide molecules are critical for the optimal inhibitory
activity of the pentavalent construct. Interestingly, replacement of L-amino acid residues by D-amino acids or reduction of
the peptide bond between the first two amino acids of the tripeptide generated peptide-TASP analogs active at sub-mM,
concentrations. The anti-HIV action of the peptide-TASP constructs is specific, since they inhibit infection of several types
of CD4-expressing cells by HIV-1 Lai and HIV-2 EHO but not by the simian SIV-mac isolate. Our results suggest that these
inhibitors block three post-CD4 binding functions of the HIV envelope glycoproteins, mediation of viral entry, syncytium
formation, and triggering cell death by apoptosis. As the peptide-TASP derivatives with unnatural amino acid sequences in
the tripeptide moiety retain full inhibitory activity, they should provide potent protease-resistant peptide inhibitors as potential
therapeutic agents for treatment of AIDS patients. q 1996 Academic Press, Inc.
INTRODUCTION face-expressed envelope glycoprotein complex is also
responsible for the initiation of cell death by apoptosis
The human immunodeficiency virus (HIV) env gene occurring in HIV-infected cell cultures (Hovanessian,
codes for a precursor polyprotein which is processed by 1994). Although, the initiation of syncytium formation and
proteolytic cleavage to yield the extracellular and trans- apoptosis may occur simultaneously during HIV infec-
membrane glycoproteins (for a review see Moore et al., tion, these two processes are distinct functions of the
1993). The extracellular glycoprotein contains the binding HIV envelope complex (Laurent-Crawford et al., 1993;
site for the CD4 receptor and a hypervariable region of Corbeil and Richman, 1995). In support of this, apoptosis
about 36 amino acids referred to as the V3 loop (Moore has been demonstrated in CD4/ T cells infected with
and Nara, 1991), whereas the transmembrane glycopro- either syncytium-inducing and non-syncytium-inducing
tein contains a potential fusion peptide at its amino termi- HIV isolates, and in both cases antibodies against the
nus which is implicated in the membrane fusion process extracellular envelope glycoprotein or the CD4 receptor
(Freed et al., 1991). The extracellular and transmembrane block initiation of apoptosis (Rey-Cuille´ et al., 1994).
glycoproteins are associated in a noncovalent manner Taken together, these observations indicate that the viral
to generate a functional complex. For HIV particles, this envelope glycoprotein complex plays a key role in HIV
envelope glycoprotein complex is responsible for the infection. Consequently, agents which inhibit the proper
binding of the particles to the cell membrane and thus functioning of this glycoprotein complex provide the ba-
initiating virus to cell membrane fusion. In already in- sis for the development of anti-HIV drugs.
fected cells, this complex, when expressed on cell mem- The V3 loop is critical for the functioning of the HIV
branes and through interaction with cell surface CD4, is envelope glycoprotein complex, since mutations in it
responsible for the initiation of cell to cell membrane modify cell tropism, generate virions with reduced infec-
fusion, leading to the formation of syncytia. A cell-sur- tivity, and affect syncytium formation and induction of
apoptosis (Chesebro et al., 1992; Grimalia et al., 1992;
De Jong et al., 1992; Laurent-Crawford et al., 1995). Thus,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (33-1)4061-3012. the V3 loop might be implicated in post-CD4 binding
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events by interacting with some hypothetical cell-surface TASP inhibitors is at the stage of viral entry without ex-
erting adverse effects on cell metabolism and viability.components, and several reports have proposed such
potential candidates, such as membrane-expressed pro- The 5(KPR)-TASP molecule was investigated as a model
in structure and HIV-inhibitory-activity relationship stud-teases tryptase TL2 and cathepsin G, the T cell activation
antigen CD26, and some unidentified proteins, as cofac- ies to define the characteristics of the inhibitory mole-
cule. By these studies, we were able to generate prote-tors of the CD4 receptor (Hattori et al., 1989; Kido et al.,
1990; Avril et al., 1994; Callebaut et al., 1993; Xu et al., ase-resistant peptide molecules which inhibit HIV infec-
tion at submicromolar concentrations.1995). CD26, also known as dipeptidyl peptidase IV (DPP
IV), has the capacity to cleave synthetic peptide sub-
strates provided that the penultimate residue is proline MATERIALS AND METHODS
(Brandt et al., 1992). In view of this, we have previously
Cellspointed out the presence of highly conserved RP, GP,
and KP dipeptide motifs in the V3 loop sequences among CEM cells (clone 13) derived from human lymphoid
different HIV-1, HIV-2, and simian immunodeficiency vi- cell line CEM (ATCC-CCL 119) and MOLT4-T4 clone 8
rus (SIV) isolates (Myers et al., 1994) and suggested that cells selected from MOLT4 cells for a high level of CD4
such motifs may provide the sites in the V3 loop which expression were provided by Dr. L. Montagnier, Institut
could mediate interaction with CD26 (Callebaut et al., Pasteur, France. C8166 cells (from Dr. G. Farrar) were
1993, 1994a). Consistent with this, a synthetic V3 loop generously provided by the MRC AIDS Directed Pro-
peptide was shown to bind the catalytic domain of CD26 gramme Reagent Project (UK). CEMx174 cells, a fusion
(Chin et al., 1995). Previously, other groups have con- product of human B cell line 721.174 and human T cell
tested our findings; their critiques with our response have line CEM, were used because of their permissiveness
been published (Broder et al., 1994; Callebaut et al., to SIV infection (Daniel et al., 1985) and were obtained
1994b). More recently, however, the implication of CD26 from L. Chakrabarti, Institut Pasteur. Chronically HIV-1-
along with the V3 loop has been further emphasized for infected H9/IIIB cells were obtained from Dr. R. C. Gallo
HIV entry and its cytopathic effect (Oravecz et al., 1995). (National Institute of Health, Bethesda, MD; Resnick et
Synthetic tripeptides RPR, RPK, and KPR, which pro- al., 1986). All cells were cultured in suspension medium
vide the conserved RP dipeptide or a related motif in the RPMI 1640 (Bio-Whittaker, Verviers, Belgium) containing
V3 loop, were shown to inhibit the DPP IV activity of CD26 10% (v/v) fetal calf serum.
and also block HIV entry at millimolar concentrations.
In an attempt to increase the inhibitory activity of such Virus infection
peptides, we designed and synthesized a construction
referred to as TASP for ‘‘template assembled synthetic The HIV-1 Lai isolate previously referred to as HIV-1
Bru (Wain-Hobson et al., 1991) was used in this study. Apeptide,’’ in which a lysine-rich decapeptide or hexapep-
tide was used as a template to covalently anchor several highly infectious preparation of HIV-1 was generated by
several consecutive passages of the original HIV-1 Laimolecules of RPR or KPR at the e-amino groups of the
lysine residues in the templates. The pentavalent presen- isolate on CEM cells in culture medium containing 2 mg/
ml polybrene (Sigma). This highly infectious virus wastation, such as 5(RPR)-, 5(RPK)-, or 5(KPR)-TASP, gave
maximum inhibitory activity on HIV infection compared characterized by its capacity to generate a synchronous
infection in CEM cells; i.e., all cells become infected byto the octavalent, tetravalent, or trivalent presentations,
thus indicating that the pentavalent presentation of the the input virus, and at 2– 3 days postinfection (p.i.) more
than 90% of cells become producers of HIV proteinstripeptides generates a conformation which is optimal
for the inhibitory molecule. Such pentavalently presented (Laurent-Crawford and Hovanessian, 1993). One syn-
chronous infectious dose on 106 CEM cells containedtripeptide-TASP constructs, however, did not affect the
DPP IV activity of CD26. Thus, although 5(RPR)-TASP and 200 ng of the HIV-1 major core protein p24. The concen-
tration of p24 was measured by p24 Core Profile ELISArelated TASP constructs were originally designed after
the monomer tripeptides RPR or KPR, these observations (DuPont).
The stock of HIV-2 EHO isolate was prepared by infec-suggest that they might have different modes of action.
Indeed, experiments in progress favor the conclusion tion of CEM cells (Rey-Cuille´ et al., 1994), whereas the
SIV-mac isolate was propagated on CD4-expressing hu-that the peptide-TASP inhibitors bind to a cell-surface
protein distinct from CD26 (manuscript in preparation). man lymphoid HUT-78 cells (Daniel et al., 1985). The HIV-
2 EHO and SIV-mac infections were carried out in theHere, we have shown that the peptide-TASP constructs,
by binding to a cell-surface component, block viral entry presence of 2 mg/ml of polybrene. The amount of HIV-2
and SIV isolates was estimated by the reverse tran-and infection of HIV but not SIV isolates. Addition of the
same peptide-TASP constructs after viral entry has no scriptase activity or by measuring the concentration of
viral major core protein (p26 for HIV-2; p27 for SIV usingsignificant effect on HIV infection. Taken together, our
results indicate that the anti-HIV action of the peptide- SIV p27 Core Profile ELISA, Coulter).
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Peripheral blood mononuclear cells (PBMC) from logs on the template. The Boc protecting groups of the
template PAM resin were cleaved in 60% trifluoroacetichealthy donors were prepared by Ficoll– Hypaque den-
sity gradient centrifugation and suspended in RPMI 1640 acid in dichloromethane for 30 min and then the resin
was washed with dichloromethane and dimethylform-medium containing 10% fetal calf serum. PBMC were
stimulated with PHA (10 ng/ml) and cultured for 3 days, amide. The elongation of the peptide chains was
achieved using a fivefold excess of Boc amino acid deriv-at which time the culture medium was replaced by fresh
medium containing 10% (v/v) T cell growth factor (Bio- atives.
Reduced peptide bond pseudopeptide analoguestest). PBMC cultures were then infected with the different
primary isolates of HIV-1 (material equivalent to 25 –50 were also synthesized by the solid-phase chemistry. The
reduced peptide bond was formed on the resin by reduc-ng of p24 per 106 cells) by incubating at 377 for 1 hr,
before removal of the unbound virus by centrifugation tive amination of N-Boc-a-aminoaldehydes (2.5-fold ex-
cess) in dimethylformamide containing 1% acetic acid asand suspension in fresh culture medium. Infected cul-
tures were kept at 377 and virus production was moni- described previously (Sasaki and Coy, 1987; Guichard et
al., 1993, 1995). Typically, the reaction was completetored by measuring the concentration of p24 in the cul-
ture supernatant. Two primary HIV-1 isolates were used: within 1 hr as observed by the ninhydrin test. The synthe-
sis of peptide-TASP constructs in D-configuration wasa syncytium-inducing isolate from Uganda (92UGO29A)
and a non-syncytium-inducing isolate from Brazil carried out using the same strategy.
At the end of the synthesis and after the last depro-(92BRO25C). These isolates were obtained through the
AIDS Research and Reference Reagent Program, Divi- tection step, the peptide resin was washed twice with
ether and dried under vacuum. The peptides weresion of AIDS, NIAID, NIH: International HIV-1 Isolate
Panel (Osmanov et al., 1994). cleaved from the resin by treatment with anhydrous
hydrogen fluoride containing 10% (v/v) anisol and 1%
(v/v) 1,2-ethanedithiol. After lyophilization, the peptidesSynthesis of peptide-TASP constructs
were purified by reverse phase HPLC using a Perkin –
The TASP approach (Mutter, 1985) had originally been Elmer preparative HPLC system on an Aquapore ODS
developed to transfer enzyme-specific characteristics to 20-mm column (100 1 10 mm) by elution with a linear
more easily accessible molecules and thus to construct gradient of aqueous 0.06% trifluoroacetic acid (A) and
new proteins and enzymes. On this basis, we have used 80% acetonitrile in trifluoroacetic acid (B), at a flow rate
a lysine-rich template to covalently anchor arrays of tri- of 6 ml/min with UV detection at 220 nm. Analytical
peptides which as monomers inhibit HIV entry in CD4/ HPLC was run on a Beckman instrument (Gagny,
cells at a relatively high molarity (10 mM) and are also France) with a Nucleosil C18 5-mm column (3.9 1 150
substrates/inhibitors of the DPP IV activity of CD26 mm) using a linear gradient of 0.1% trifluoroacetic acid
(Callebaut et al., 1993). Here only a brief description of (A) and acetonitrile containing 0.08% trifluoroacetic
these TASP constructs is given. acid (B), at a flow rate of 1.2 ml/min. Ion-spray mass
(A) Assembly of the template. The protected peptide spectra were obtained on a VG B10-Q quadruple mass
template was synthesized by combining t-butyloxy- spectrometer (VG Analytical Ltd., UK).
carbonyl (Boc) and Na-9-fluorenylmethyloxycarbonyl
(Fmoc) solid-phase methodology. Protected amino
Assay of HIV entryacids were from Neosystem (Strasbourg, France) and
Boc-Cys(4-MeBzl) PAM resin was from Perkin – Elmer HIV-1 entry was monitored by two different techniques.
(Saint Quentin en Yvelines, France). Assembly of the In the first method, HIV entry was estimated by measur-
protected peptide chains was carried out on a 200- ing the intracellular concentration of p24 (Callebaut et
mmol scale as described previously (Neimark and Bri- al., 1993), after 1 hr incubation of CEM cells (5 1 106/ml)
and, 1993). The structure of the protected peptide tem- with one infectious dose of HIV-1 Lai (corresponding to
plate is shown below. 200 ng of p24). In the second method, HeLa-CD4-LTR-
b-gal cells (from Dr. F. Clavel, Institut Pasteur, Paris)
containing the bacterial lacZ gene under the control of
HIV-1 LTR were used to monitor HIV entry in an indirect
Boc Boc Boc Boc
w w w w
10 9 8 7 6 5 4 3 2 1
Boc{K{K{K{G{P{K{E { K{G{C{PAM–Resin
w w w
C l z O–cHex 4–MeBzl
manner, i.e., by the expression of b-galactosidase
(Dragic et al., 1992). Cells were plated at 5 1 104 cells/
well in a 24-well plate, and 48 hr later cell monolayers
were infected with HIV-1 Lai (a dose containing 50 ng ofThe following side chain protecting groups were used:
cyclohexyl ester (Glu 4), (chlorobenzyloxycarbonyl (Lys p24). Twenty-four hours p.i., cell monolayers were
washed with PBS and cytoplasmic extracts were pre-9), t-butyloxycarbonyl (Lys, 3, 5, 8). The lys 10 was intro-
duced as a Boc Lys (Boc) derivative. pared by the addition of a cell lysis buffer containing 1%
Triton X-100 (v/v), 60 mM Na2HPO4, 40 mM NaH2PO4, 10(B) Multiple assembly of the tripeptides or their ana-
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mM KCl, 1 mM MgCl2 , and 50 mM b-mercaptoethanol.
After centrifugation (12,000 g, for 5 min), aliquots were
assayed for b-galactosidase activity (after diluting in the
above buffer but without Triton) by incubating with o-
nitrophenyl b-D-galactopyranoside (Sigma) at 377 for 1
hr. This suspension was then centrifuged before measur-
ing the absorption at OD 420 nm.
Assay of the inhibitory effect of peptide-TASP
constructs on HIV infection
CEM cells were first incubated (10 – 15 min, at room
temperature) in the presence of different concentrations
of the peptide-TASP constructs in culture medium con-
taining 2 mg/ml polybrene before the addition of one
synchronous dose of HIV-1 Lai (as described above). The
cells were further incubated (60– 90 min, 377) with gentle
agitation, centrifuged (350 g, 5 min), and suspended in
fresh culture medium containing different concentrations
of each construct. HIV production was measured at 4
days p.i. All estimations for the 50% inhibitory concentra-
tion dose (IC50) values were carried out at experimental
FIG. 1. Schematic structure of 5(KPR)-TASP and 5(RPK)-TASPm mole-conditions using one infectious dose of HIV-1 (Laurent-
cules. Pentavalent presentation of KPR, RPK, or RPR using the tem-Crawford and Hovanessian, 1993).
plates KKKGPKEKGC and KKKKGC was found to generate biologically
active molecules (see Table 1). The central GP sequence in the KKK-
Cell viability assay GPKEKGC template was initially incorporated to facilitate the formation
of a reverse-turn structure (Dawson and Kent, 1993). This latter, how-The viability of CEM (clone 13) cells cultured in 96-
ever, was found not to be necessary as the construct with the modified
well microtiter plates in the presence of different concen- template (TASPm) manifested equivalent activity.
trations of the peptide-TASP constructs was monitored
by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) assay as described previously (Schwartz the template. Such pentavalently presented molecules
et al., 1988). are referred to as 5(RPR)-TASP, 5(RPK)-TASP, and
5(KPR)-TASP, respectively. In later experiments, the tri-
Monitoring the effect of peptide-TASP constructs on
peptides were anchored on an hexapeptide template
syncytium formation and cell death by apoptosis in
(KKKKGC), and such constructs are referred to as pep-
cocultures of H9/IIIB and CEM cells
tide-TASPm (Fig. 1). The different constructs were tested
for their activity on HIV entry by measuring the intracellu-In a typical coculturing experiment, 0.5 1 106 chroni-
lar concentration of HIV-1 major core protein p24 after 1cally infected H9/IIIB cells were mixed with 5 1 106 CEM
hr of incubation with the input virus (Table 1). Interest-cells in 5 ml of culture medium (RPMI 1640 containing
ingly, more than 90% inhibition of HIV entry was observed10% fetal calf serum). The cocultures were incubated at
at 30 mM 5(RPR)-TASP and 5(KPR)-TASP, with IC50 values377 and monitored for the development of the cytopathic
at 5 and 10 mM, respectively. The template alone had noeffect manifested by the syncytium formation and bal-
effect, whereas the tripeptide monomers RPR and KPRlooning of cells. At 24 hr apoptosis was monitored by
inhibited HIV entry only when used at millimolar concen-assaying for the presence of nucleosomal histones (H2A,
trations, with IC50 values at 6 and 7 mM.H2B, H3, and H4) in the nucleoplasm of cells, as de-
The effect of 5(RPR)-TASP and 5(KPR)-TASP was alsoscribed previously (Laurent-Crawford et al., 1993, 1995).
tested on the HeLa CD4 positive cell line (HeLa-CD4-
LTR-b-gal) expressing the bacterial lacZ gene placed un-RESULTS
der the control of the HIV-1 LTR (Dragic et al., 1992).
The construction of peptide-TASP inhibitors of HIV
Upon HIV infection of these cells, the viral transactivator
entry
Tat induces the lacZ gene to express b-galactosidase
which then can be monitored by an enzymatic assay.We designed and synthesized a construction referred
In this particular system in which the expression of b-to as TASP, for template assembled synthetic peptide,
galactosidase is dependent on HIV entry and replication,in which a lysine-rich decapeptide (KKKGPKEKGC) was
both 5(RPR)-TASP and 5(KPR)-TASP produced a signifi-used to covalently anchor five molecules of RPR, RPK,
or KPR at the e-amino groups of the lysine residues in cant inhibition of b-galactosidase activity (Table 1).
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TABLE 1 deed, preliminary results suggest that peptide-TASP con-
structs inhibit HIV entry by acting on a cell-surface pro-The Effect of Different Synthetic Peptides on the HIV Entry in CEM
tein other than CD26 (manuscript in preparation).and HeLa-CD4-LTR-b-gal Cells and on the DPP IV Activity of CD26
HIV entry b-Galactosidase DPP IV activity 5(KPR)-TASP inhibits HIV-1 infection by blocking viral
Peptide (IC50) (IC50) (IC50) entry
KPR 7 mM N.D. 200 mM Infection of CEM cells with a high dose of HIV-1 Lai
RPR 6 mM N.D. 200 mM results in a synchronous type of infection, in which most
5(G)-TASP No effecta No effecta No effecta
cells become infected within 6 to 8 hr, and by 2 to 3 days5(KPR)-TASP 10 mM 10 mM No effecta
more than 90% of cells become positive for the synthesis5(RPR)-TASP 5 mM 10 mM No effecta
of viral proteins (Laurent-Crawford and Hovanessian,
Note. The effect of different peptides on HIV-Lai entry was monitored 1993). In such an infection, different doses of 5(KPR)-
either directly by measuring the intracellular concentration of p24 in TASP were added either 10 min before or 8 hr after
CEM cells or indirectly by measuring the b-galactosidase activity in
incubation with the input virus, and the production ofHeLa-CD4-LTR-b-gal cells. In the absence of peptides, the mean values
virus was monitored by measuring the concentration offor p24 and b-galactosidase activity were 185 { 36 pg/105 cells and
0.2 { 0.03 OD at 420 nm per 50 ml extract (corresponding to 5 1 104 p24 in the culture medium (Fig. 2). When added before
cells), respectively. The DPP IV activity was monitored by the cleavage virus, the production of HIV was inhibited by more than
of the substrate GP-pNA using crude cell extracts from MOLT4 cells. 50 and 90% at 5 and 20 mM 5(KPR)-TASP, respectively,
The mean value for the DPP IV activity was 56 { 8 nmol GP cleavage
whereas the production of HIV was not affected whenper 25 ml extract (corresponding to 106 cells). All the methods were as
the inhibitor was added 8 hr p.i. The results of thesedescribed under Materials and Methods. The 5(G)-TASP construct was
used as a control to demonstrate that the template KKKGPKEKGC has experiments confirm those of Table 1 and illustrate that
no effect on HIV entry. N.D., not done. the mechanism of action of 5(KPR)-TASP is mainly di-
a No effect at 5 mM.
5(KPR)-TASP and 5(RPR)-TASP inhibit HIV entry by
binding to a cell-surface component
In order to demonstrate that 5(KPR)-TASP and 5(RPR)-
TASP inhibit HIV entry by binding to the cell membrane,
CEM cells were first incubated with these inhibitors (25
mM) at 47 for 30 min, before washing in culture medium
and assay for HIV entry. Under these latter experimental
conditions, HIV entry was blocked by more than 85%
(data not shown), thus suggesting that these inhibitors
exert their anti-HIV action by interacting with a cell-sur-
face component. The effect of peptide-TASP inhibitors
was also investigated on the binding of 125I-labeled gp120
to HIV-permissive, CD4/ T lymphocytes (experimental
conditions as described in Fig. 5; Callebaut et al., 1993).
The binding of gp120 to CEM or other CD4/ human cells
was found not to be affected in the presence of 50 to
100 mM 5(KPR)-TASP or 5(RPR)-TASP (data not shown).
These inhibitors, therefore, block HIV entry by acting on
a post-CD4 binding event necessary for the fusion of
virus to cell membranes.
The tripeptides KPR and RPR are potential substrates
of DPP IV activity of CD26 because they contain a penulti-
FIG. 2. 5(KPR)-TASP inhibits HIV-1 infection when added before butmate proline residue (Brandt et al., 1992). Consequently,
not after viral entry. CEM cells were infected with 1 synchronous infec-
such peptides are competitive inhibitors for the cleavage tious dose of HIV-1 Lai (containing 200 ng of p24 per 106 cells) which
of conventional synthetic substrate GP-pNA (Rahfeld et results in a synchronous infection characterized by the production of
a maximum amount of virus by more than 90% of cells (Materials andal., 1991). In contrast to the tripeptide monomers, how-
Methods). Treatment of cells with different doses of 5(KPR)-TASP (ab-ever, 5(KPR)-TASP and 5(RPR)-TASP molecules had no
scissa) was carried out either 10 min before (s) or 8 hr after (l) theeffect on DPP IV activity (Table 1). This latter is most
addition of virus, and the production of HIV was monitored by measur-
probably due to the distinct structural features of the ing the concentration of p24 in the culture supernatant at 4 days p.i.
monovalent and pentavalent peptide molecules and sug- (the ordinate). Each point represents the mean of two infections carried
out in parallel.gests that there might be different modes of action. In-
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TABLE 2rected against the viral entry process. The observation
that HIV production was not affected in infected cells Inhibitory Activity of 5(KPR)-TASP and Related
when 5(KPR)-TASP was added 8 hr p.i. indicated that this Peptide-TASP Constructs
inhibitor does not have adverse effects on cells.
Inhibition of HIV productionIn CEM cells infected with HIV-1 Lai, syncytium forma-
in CEM cellstion is tightly correlated with the cell-surface expression
of HIV-1 external and transmembrane glycoproteins, the Peptide construct Concentration: 25 mM IC50
gp120/gp41 complex (Laurent-Crawford and Hovanes-
5(G)-TASP Nonea N.A.sian, 1993). Syncytium formation, monitored by light mi-
5(KPR)-TASP 85% 5 mMcroscopy, was drastically inhibited when 5(KPR)-TASP
5(RPK)-TASP 97% 1 mMwas added before virus (consistent with the inhibition of
5(RPK)-TASPm 98% 1.5 mMvirus infection). Interestingly, syncytium formation was 5(RPR)-TASP 95% 2 mM
also inhibited in HIV-infected cultures when 5(KPR)-TASP 8(KPRG)-TASP 70% 10 mM
4(RPK)-TASP 40% 50 mMwas added 8 hr after virus, thus suggesting that as the
3(KPR)-TASP Noneb 100 mMvirus to cell membrane fusion, this inhibitor can also
5(KPQ)-TASP Noneb 100 mMaffect the cell to cell membrane fusion process.
5(QPQ)-TASP Nonea N.A.
5(aAcRPK)-TASP 59% 20 mM
5(eAcKPR)-TASP Noneb 100 mMCharacterization of 5(KPR)-TASP by structure and
5(KGR)-TASP 70% 20 mMactivity relationship studies
5(KER)-TASP 50% 25 mM
5(RK)-TASP 77% 10 mM5(KPR)-TASP peptide was taken as a model to charac-
5(PKR)-TASP 75% 10 mM
terize the structural requirements of an inhibitory mole- 5[K-c(CH2N)PR]-TASP 99% 0.5 mM
cule with maximal activity on HIV-1 Lai infection. For 5[R-c(CH2N)PK]-TASPm 99% 0.5 mM
5[(D)R(D)P(D)K]-TASP 98% 2 mMthis purpose, we synthesized a series of peptide-TASP
5[(D)K(cCH2N)(D)P(D)R]-TASPm 99% 0.5 mMmolecules in which the individual amino acids in the KPR
tripeptide moiety were replaced by other residues, and
Note. The inhibitory activity of different constructs was tested against
the a-amino group of the first basic residue or the e- HIV-1 Lai infection as described in Fig. 2. Different concentrations (0.1,
amino group of the K residue was blocked by acetylation. 0.5, 1, 2, 5, 10, 25, 50, and 100 mM) of each construct were added to
CEM cells 10 –15 min before the addition of HIV-1. The production ofWe also prepared pseudopeptide 5(KPR)-TASP ana-
HIV (measured by the concentration of p24) was monitored at 4 days p.i.logues by reduction of the peptide bond between the
in the culture supernatants. The percentage inhibition of HIV productionfirst two amino acids of the tripeptide KPR and/or by
observed at 25 mM and the IC50 value for the inhibitory molecules arereplacement of L-amino acid residues by D-amino acids. given. The template in the case of 8(KPRG)-TASP was KKKKGPKKKKGA,
All the different constructs were tested for their capacity in order to anchor KPRG peptides on each of the lysine residues of
the template. N.A., not applicable since these peptides have no effectto inhibit HIV-1 Lai infection in CEM cells. Table 2 gives
on HIV infection.the percentage inhibition of virus production observed at
a No effect at 100 mM.a 25 mM concentration of each of the peptides along b No effect at 50 mM.
with their respective IC50 value.
These structure– function studies (Table 2) indicated
that the pentavalent presentation of KPR, RPK, or RPR duced the inhibitory activity, thus suggesting that these
basic side chain groups play a critical role in the inhibi-generated a conformation which is optimal for maximum
inhibitory activity. The octavalent presentation did not tory structure. Replacement of the P residue by G or E,
deletion, or shifting its position in the tripeptide gener-generate a more active molecule, whereas tetravalent
and trivalent presentation significantly reduced the inhib- ated molecules 5(KGR)-TASP, 5(KER)-TASP, 5(RK)-TASP,
and 5(PKR)-TASP that manifested 4- to 10-fold reductionitory activity. Furthermore, the K and R residues in the
tripeptide KPR could be interchanged without losing ac- of activity compared to that of the 5(KPR)-TASP and
5(RPK)-TASP molecules. Therefore, the P residue in thetivity. As a matter of fact, 5(RPR)-TASP manifested a
slightly higher activity compared to that of 5(KPR)-TASP. tripeptide, though not essential, might favor the genera-
tion of a more stable and optimal configuration. Consis-However, replacement of one or both of these basic resi-
dues by another hydrophilic residue like glutamine, such tent with this, it has been suggested that P residues
confer unique structural constraints on peptide chainsas 5(KPQ)-TASP and 5(QPQ)-TASP, drastically reduced
the inhibitory activity. Acetylation of the a-amino group (Yaron and Naider, 1993). Interestingly, the construction
made up of the D-enantiomer of the tripeptide RPK wasin the tripeptide did not seem to be very crucial, although
the acetylated peptide 5(aAcRPK)-TASP manifested a re- found as active as the construction made of the L-config-
uration, whereas reduction of the peptide bond betweenduced activity compared to that of the 5(RPK)-TASP con-
struct. On the other hand, acetylation of the e-amino amino acids 1 and 2 resulted in a molecule with the
highest inhibitory activity (IC50 0.5 mM). Taken together,group of the K residues, 5(eAcKPR)-TASP, drastically re-
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servations are consistent with the specificity of the pep-
tide-TASP inhibitors to interact with a cell-surface com-
ponent.
Peptide-TASP inhibitors block HIV-1 and HIV-2 but
not SIV infection
The effect of 5(KPR)-TASP and 5[Kc(CH2N)PR]-TASP
was tested in parallel on HIV-1 Lai and HIV-2 EHO infec-
tion in CEM cells. The construct 5(KPQ)-TASP was used
as a control peptide (Fig. 4). These infections were opti-
mized in order to obtain somewhat comparable infec-
tions, in which maximum virus production occurred at
Day 7 p.i. In the presence of 5(KPR)-TASP and its reduced
derivative, there was a drastic inhibition of both HIV-1
and HIV-2 infection. Since HIV-1 and HIV-2 represent theFIG. 3. Inhibition of HIV infection by the peptide-TASP construct
two major distinct types of HIV, it is possible to suggestoccurs in the absence of an effect on cell viability. CEM cells were
incubated (15 min) with different concentrations of 5[Kc(CH2N)PR]- that 5(KPR)-TASP and related peptide molecules could
TASP before infection with HIV-1 Lai (as in Fig. 2). Virus production
(measured by the concentration of p24; the left ordinate) and the MTT
assay for cell viability (measured by OD 540 nm; the right ordinate)
were carried out at 4 days p.i. Each point represents the mean of
duplicate and quadruplicate samples for the p24 and the MTT assays,
respectively.
the data shown in Table 2 demonstrate that the inhibitory
molecule requires pentavalently presented tripeptides
with free positively charged side chains.
The effect of peptide-TASP inhibitors on cell viability
and the activity of membrane-expressed enzymes
The different peptide-TASP constructs were also
tested for their effect on cell viability by the MTT assay
(Schwartz et al., 1988). In general, there was a close
correlation between HIV inhibitory activity of a given pep-
tide and its toxicity on cells, and active peptides were
found to affect cell viability at concentrations higher than
50 mM. However, it should be emphasized that at the
concentration of a given inhibitor which resulted more
than 90% inhibition of HIV infection, no apparent effect
was observed on cell viability. A typical result is shown
in Fig. 3, using 5[Kc(CH2N)PR]-TASP as the inhibitory
molecule. This peptide exerted more than 95% inhibition
at 5 mM with an IC50 value of 0.5 mM. Cell viability in
these infected cells was not affected by the presence of FIG. 4. The peptide-TASP inhibitors block infection of CEM cells by
both HIV-1 and HIV-2. CEM cells were incubated (15 min) with theup to 20 mM 5[Kc(CH2N)PR]-TASP.
different constructs before infection with HIV-1 Lai (a viral dose con-The activity of several cell-surface-expressed pepti-
taining 40 ng of p24 per 106 cells) or HIV-2 EHO (a viral dose containingdases was monitored in order to assess any nonspecific
20 ng of the HIV-2 major core protein p26 per 106 cells; Rey-Cuille´ et
effects of the peptide-TASP inhibitors. For this purpose al., 1994). The doses of HIV-1 and HIV-2 were optimized to obtain a
CEM cells were incubated with GP-pNA, A-pNA, R-pNA, similar kinetics of infections (s). At different days p.i. (abscissa), culture
supernatants were assayed for the production of virus by measuringand AAF-pNA as substrates for DPP IV, alanyl-peptidase,
the reverse transcriptase activity. The peptide-TASP constructs werearginine-peptidase, and tripeptidyl endopeptidase, re-
the following: 5(KPR)-TASP at 5 ( ) and 10 ( ) mM; 5[Kc(CH2N)PR]-spectively (Bauvois et al., 1992). None of the peptide-
TASP at 5 (l) and 10 (j) mM; 5(KPQ)-TASP (h) 20 mM as a control
TASP inhibitors, even at concentrations higher than 100 inactive molecule. The reduction of virus production at later points in
mM, had any apparent effect on these enzymes cleaving the control samples (s and h) is most probably due to cell death
occurring during the peak of virus production which was at 7 days p.i.their respective substrates (data not shown). These ob-
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TABLE 3
Peptide-TASP Inhibitors Block HIV-1 but Not SIV Infection
Virus production
Cells Virus Peptide-TASP RT (cpm) or p24 (ng/ml)
CEMx174 HIV-1 Lai None 36,586 cpm
5(KPQ)-TASP 32,448 cpm
5(RPK)-TASP 6584 cpm (82%)a
SIV-mac None 20,561 cpm
5(KPQ)-TASP 22,351 cpm
5(RPK)-TASP 25,782 cpm
C8166 HIV-1 Lai None 352 ng/ml
5(KPQ)-TASP 374 ng/ml
5(RPK)-TASP 43 ng/ml (88%)a
5[Kc(CH2N)PR]-TASP 32 ng/ml (91%)a
SIV-mac None 144,620 cpm
5(KPQ)-TASP 151,055 cpm
5(RPK)-TASP 170,775 cpm
5[Kc(CH2N)PR]-TASP 167,660 cpm
Note. SIV-mac permissive CEMx174 and C8166 cells were infected with HIV-1 Lai or SIV-mac (doses containing 20 ng of the HIV or SIV major
core proteins, p24 or p27 per 106 cells) in the absence or presence of 5(RPK)-TASP and 5[Kc(CH2N)PR]-TASP molecules. HIV-1 production was
monitored either by the reverse transcriptase activity in the culture supernatant of C8166 cells or by the concentration of p24 in the culture
supernatant of CEMx174 cells at 5 days p.i. The production of SIV-mac was monitored by the reverse transcriptase activity in the culture supernatants
at 10 days p.i. The concentrations of peptide-TASP constructs were 20 and 10 mM in CEM/174 and C8166 cells, respectively. The SIV-mac infection
was not inhibited by peptide-TASP inhibitors, and even some constructs resulted in a slight enhancement of viral production.
a % inhibition of virus production.
manifest an inhibitory activity on different subtypes and The effect of peptide-TASP inhibitors on syncytium
formation and cell death by apoptosisisolates of HIV.
In order to investigate the effect of peptide-TASP inhib-
Chronically HIV-1-infected H9/IIIB cells, because of theitors on SIV-mac infection, we used two types of hu-
expression of membrane gp120/gp41 complex, are ef-man cells permissive to both human and simian iso-
fector cells capable of inducing syncytium formation andlates: CEM1174 and C8166 cells. Although HIV-1 Lai
apoptosis when cocultured with uninfected CD4/ T cellinfection was inhibited drastically by 5(KPR)-TASP and
lines (Hovanessian, 1994; Maldarelli et al., 1995). For this5[Kc(CH2N)PR]-TASP in these cells, no apparent effect
purpose, H9/IIIB cells were cocultured with CEM cellswas observed on SIV-mac infection (Table 3). These re-
for 24 hr in the absence or presence of peptide-TASPsults illustrate that the inhibitory effect of 5(KPR)-TASP
inhibitors. Syncytium formation and ballooning of cellsand related peptides is specific to the immunodeficiency
was then monitored by light microscopy, whereasviruses of human origin. Furthermore, the results might
apoptosis was assayed by analyzing the presence ofreflect some differences in the mechanism of viral entry
nucleosomal histones in the nucleoplasma fractions ofbetween HIV and SIV, as it has been reported previously
the cocultured cells (Figs. 6 and 7).(Buckheit et al., 1994).
The peptide-TASP inhibitors blocked syncytium forma-
tion in a dose-dependent manner with maximal effects
Peptide-TASP inhibitors block infection of PBMC by at 20 mM. A typical result is shown in Fig. 6, using
primary HIV-1 isolates 5[Kc(CH2N)PR]-TASP. It should be noted that at 10 and
20 mM concentrations of 5[Kc(CH2N)PR]-TASP, there
Syncytium-inducing (SI) and non-syncytium-inducing were aggregates of cells without formation of syncytia.
(NSI) primary HIV-1 isolates were employed to study the Since peptide-TASP inhibitors did not affect the binding
effect of peptide-TASP inhibitors in an in vitro infection of gp120 to CD4, such aggregates are most probably the
of PBMC cultures. A typical result is shown in Fig. 5, consequence of the binding of the gp120/gp41 complex
using 5[(D)K(cCH2N)(D)P(D)R]-TASPm (described in Ta- on the chronically infected cells with the CD4 receptor
ble 2). At 12 days p.i., the production of the SI and the on CEM cells. Apoptosis monitored by the presence of
NSI isolates was reduced by more than 90% at a 10 mM histones associated with low-molecular-weight DNA in
concentration of this inhibitor (Fig. 5); the IC50 values the nucleoplasm (Laurent-Crawford et al., 1993) was also
were 2.5 and 5 mM for the inhibition of the SI and the inhibited in a dose-dependent manner with a complete
inhibition at 20 mM 5[Kc(CH2N)PR]-TASP in D-configura-NSI isolates, respectively (not shown).
AID VY 7814 / 6a13$$$403 03-04-96 18:24:44 vira AP: Virology
189PEPTIDE INHIBITORS OF HIV INFECTION
role in the inhibitory structure. As 5(KPR)-TASP and
5(RPR)-TASP were active at concentrations at least 1000-
fold lower than the tripeptides KPR and RPR, it is possible
to suggest that the structure by which these positive
charges are presented but not the amount of the charge
is critical. Since the pentavalent presentations of RPR or
KPR have maximum inhibitory activity they should fulfill
the requirements for optimum presentation of the
charges in the tertiary structure of the inhibitory mole-
cule.
The different peptide-TASP inhibitors were character-
ized by their capacity to block infection of several types
of CD4/ cells by HIV-1 Lai and HIV-2 EHO, but not the
SIV-mac isolate. These inhibitory molecules, therefore,
block a defined target implicated in the entry of suchFIG. 5. Infection of PBMC cultures by primary isolates is inhibited
viruses of human origin. The inhibition of HIV-1 Lai butby the peptide-TASP inhibitor. PBMC cultures were incubated (15 min)
not SIV-mac infection in a given cell line by 5(RPK)-TASPwith none (s), 5 ( ), and 10 (l) mM 5[(D)K(cCH2N)(D)P(D)R]-TASPm
before infection with the syncytium-inducing (SI) primary HIV-1 isolate or 5[Kc(CH2N)PR]-TASP is consistent with the specific
from Uganda (92UGO29A) or the non-syncytium-inducing (NSI) primary nature of these inhibitors and illustrates that inhibition
HIV-1 isolate from Brazil (92BRO25C; Materials and Methods). At differ- of HIV infection by such molecules is not due to adverse
ent days p.i. (abscissa), culture supernatants were assayed for the
effects on the membrane or metabolism of cells. Ourproduction of virus by measuring the concentration of p24. Note: Al-
results demonstrate that the inhibitory peptides block thethough equivalent amounts of viral particles (estimated by the concen-
tration of p24) were used to infect the PBMC cultures with the SI and three main functions of the HIV envelope glycoproteins,
NSI isolates, the kinetics and the amounts of virus produced were the external and transmembrane glycoprotein complex
not comparable. This is most probably a consequence of the specific (Hovanessian, 1994), initiation of virus/cell membrane fu-property of each virus isolate. The NSI isolates are also known to have
sion essential for HIV entry, cell/cell membrane fusiona slow/low growing phenotype in cell cultures.
resulting in syncytia, and occurrence of apoptosis. We
have previously reported that synthetic peptides con-
tion. Other inhibitors, 5(RPK)-TASP and 5[Kc(CH2N)PR]- taining GP, RP, and KP dipeptide motifs at their amino
TASP at 20 mM, manifested a similar inhibitory effect on termini, and the naturally occurring tripeptide IPI (referred
apoptosis (Fig. 7). Under similar experimental conditions, to also as diprotinin A) which is the classical inhibitor of
5(QPQ)-TASP had no effect on syncytium formation or on the DPP IV activity of CD26 (Umezawa et al., 1984), have
apoptosis (Figs. 6 and 7). the capacity to block HIV entry in CD4/ cells when used
at 10– 20 mM concentrations (Callebaut et al., 1993).
Such peptides, because of the penultimate proline resi-DISCUSSION
due, are also potential substrates of the DPP IV activity
of CD26 and consequently are competitive inhibitors forThe design of synthetic artificial polypeptides that can
fold to produce a globular tertiary structure, and thus the cleavage of the conventional synthetic substrate GP-
pNA (Rahfeld et al., 1991). Interestingly, the pentavalentlygenerate more easily accessible and biologically func-
tional molecules, has been reported in the literature (Mut- presented KPR or RPR molecules had no effect on the
DPP IV activity monitored by the cleavage of the conven-ter, 1985; Tuchscherer and Mutter, 1995). On this basis,
we have designed and synthesized a construction called tional substrate GP-pNA. This and the observations that
the 5(KPR)-TASP or 5(RPR)-TASP constructs are activeTASP, in which templates such as KKKGPKEKGC and
KKKKGC were employed to covalently anchor arrays of at 1000-fold lower concentrations against HIV than the
tripeptide monomers suggest that the monovalent andtripeptides (RPR or KPR) at the e-amino groups of the
lysine residues in the templates. The pentavalent presen- pentavalent molecules might have a distinct mode of
action, i.e., the monovalent molecules act through CD26tation, 5(RPR)-TASP and 5(KPR)-TASP, manifested maxi-
mum inhibitory activity on HIV-1 infection. Structure and whereas the pentavalent molecules act through another
cell-surface component.inhibitory-activity relationship studies using analogs of
5(KPR)-TASP indicated that the two basic residues K and Indeed, preliminary experiments have indicated that
the peptide-TASP inhibitors bind specifically to a cell-R in the tripeptide are essential. Furthermore, the K resi-
due can be replaced by R and vice versa without affecting surface protein referred to as TASP-binding protein
(TASP-BP) which appears to be distinct from CD26 (notthe inhibitory activity; however, acetylation of the e-amino
group of the K residue drastically reduces the activity of shown). Recently, multibranched peptides based on the
conserved GPGRAF motif in the V3 loop of HIV-1 Euro-the inhibitory molecule. Therefore, the positively charged
side chains of K and R residues should play a critical pean and North American isolates have been shown to
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FIG. 6. Peptide-TASP inhibitors block syncytium formation. The coculturing of CEM cells with chronically HIV-1-infected H9/IIIB cells (at a ratio of
10 to 1) was carried out in the absence [Coculture (24 hr)] or presence of 5, 10, and 20 mM 5[Kc(CH2N)PR]-TASP and 20 mM 5(QPQ)-TASP. At 24 hr
the different cultures were examined by light microscopy, and the photographs were taken. The photograph ‘‘Coculture (0 hr)’’ represents cells at the
start of the coculture. Note the presence of syncytia and the ballooning effect in the untreated [Coculture (24 hr)] and 5(QPQ)-TASP-treated cultures.
block HIV infection by interacting with the CD4 molecule CD44S (Dukes et al., 1995). The observations that the
peptide-TASP inhibitors block viral entry, syncytium for-on the cell surface (Yahi et al., 1994; Benjouad et al.,
1995). In our case, however, current experiments point mation, and initiation of apoptosis (Figs. 2– 7) indicate
that the TASP-BP should play an important role in a com-out that the TASP-BP is not the CD4 molecule (data not
shown). As the binding of gp120 to the CD4 receptor mon event implicated in HIV envelope-mediated virus/
cell and cell/cell membrane fusion processes and initia-was not affected by various peptide-TASP inhibitors, the
TASP-BP is probably a cell-surface antigen serving as a tion of apoptosis. It should be noted that, although the
peptide-TASP inhibitors were originally designed tocofactor of CD4 in the membrane fusion process to allow
viral entry. Several potential cofactors of protein in nature mimic the conserved RP dipeptide motif in the V3 loops
of HIV-1 and HIV-2 isolates, we have no indication ofhave been reported in the literature: a cell-surface prote-
ase similar to trypsin referred to as trypstase TL2 (Kido whether such peptides have the capacity to block the
potential interaction of the V3 loop with the TASP-BP.et al., 1990), CD26 (Callebaut et al., 1993; Oravecz et al.,
1995), HLA class I and class II molecules (Mann et al., Moreover, the relation of the TASP-BP with CD4, CD26, or
any other cell-surface antigen remains to be determined.1988; Corbeau et al., 1991), CD7 (Sato et al., 1994), and
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